Q-omics provides the consensus-scored ZNF503-AS2 profile across patient tissues and cancer cell-line models. ZNF503-AS2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF503-AS2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ZNF503-AS2 RNA expression shows 18,226 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where ZNF503-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF503-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF503-AS2 survival associations across molecular data types. ZNF503-AS2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF503-AS2 RNA expression–survival associations across cancer types. High ZNF503-AS2 expression shows unfavorable associations in ACC, UCEC and SKCM, but favorable associations in MESO, HNSC and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF503-AS2 RNA expression.
This table summarizes ZNF503-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF503-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF503-AS2 shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in HNSC, LIHC and LUSC. The KIRC box plot shows higher ZNF503-AS2 RNA expression in normal versus tumor tissue (log2 FC = −1.454, t-test p < 0.001).
This table shows molecular features associated with ZNF503-AS2 in patient tissues and cancer cell lines. In patient samples, ZNF503-AS2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
